Trials / Terminated
TerminatedNCT00458861
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BG9924 | Subcutaneous administration of BG9924 given every other week for 12 weeks |
| OTHER | Placebo Comparator | Subcutaneous administration of placebo given every other week for 12 weeks |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-04-11
- Last updated
- 2016-01-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00458861. Inclusion in this directory is not an endorsement.